Company Overview and News


Add ARA
to your dashboard

Headline News

American Renal Associates Holdings 2017 Q3 - Results - Earnings Call Slides

2017-11-15 seekingalpha
The following slide deck was published by American Renal Associates Holdings in conjunction with their 2017 Q3 earnings call. (4-0)

American Renal Associates' (ARA) CEO Joe Carlucci on Q3 2017 Results - Earnings Call Transcript

2017-11-15 seekingalpha
Greetings, and welcome to the American Renal Associates Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (4-0)

ARA / American Renal Associates Holdings, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-09 fintel.io
American Renal Associates Holdings, Inc. (NYSE:ARA) has 56 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 29,829,398 shares. Largest shareholders include Centerbridge Partners, L.P., FMR LLC / Fidelity Management & Research, Van Berkom & Associates Inc., TimesSquare Capital Management, LLC, and Vanguard Group Inc. (4-0)

PRO Weekly Digest: Mathematical Trades With Richard Pearson

2017-08-13 seekingalpha
How DDS is slowly going private, what a “math trade” is and why sometimes you don’t need to know what the company does to make money and Richard Pearson shares a bearish thesis on American Renal. (0-2)

American Renal Associates' (ARA) CEO Joseph Carlucci on Q2 2017 Results - Earnings Call Transcript

2017-08-10 seekingalpha
Greetings and welcome to the American Renal Second Quarter 2017 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

American Renal Associates Holdings 2017 Q2 - Results - Earnings Call Slides

2017-08-10 seekingalpha
The following slide deck was published by American Renal Associates Holdings in conjunction with their 2017 Q2 earnings call.

American Renal Associates (ARA) Looks Good: Stock Rises 8%

2017-05-12 zacks
American Renal Associates Holdings (ARA - Free Report) was a big mover last session, as the company saw its shares rise over 8% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $16.08 to $18.00 in the past one-month time frame.

American Renal Associates' (ARA) CEO Joe Carlucci on Q1 2017 Results - Earnings Call Transcript

2017-05-12 seekingalpha
Good morning, ladies and gentlemen and thank you for standing by. Welcome to the American Renal Associates First Quarter 2017 Earnings Call. [Operator Instructions] Please note this conference is being recorded. I will now turn the conference over to your host, Darren Lehrich, Senior Vice President for American Renal Associates. Thank you. You may begin.

American Renal Associates Holdings 2017 Q1 - Results - Earnings Call Slides

2017-05-12 seekingalpha
The following slide deck was published by American Renal Associates Holdings in conjunction with their 2017 Q1 earnings call.

UPDATE 1-Fresenius Medical, DaVita subpoenaed over premium assistance

2017-01-07 reuters
BERLIN/NEW YORK German's Fresenius Medical Care and U.S. rival DaVita Inc said they had both received subpoenas from federal prosecutors investigating their ties with a charity that helps patients pay for kidney dialysis.

American Renal Associates (ARA) Jumps: Stock Rises 8.7%

2016-11-14 zacks
American Renal Associates Holdings, Inc. (ARA - Free Report) was a big mover last session, as the company saw its shares rise over 8% on the day. The upside was driven after the company announced solid third-quarter 2016 results. The news also led to far more shares changing hands than in a normal session, resulting in solid volume. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $17.

DEADLINE TODAY: Lundin Law PC Announces Securities Class Action Lawsuit against American Renal Associates Holdings, Inc. and Reminds Investors with Losses to Contact the Firm

2016-10-31 accesswire
LOS ANGELES, CA / ACCESSWIRE / October 31, 2016 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against American Renal Associates Holdings, Inc. ("ARA" or the "Company") (NYSE: ARA) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired shares 1) pursuant and/or traceable to the Initial Public Offering ("IPO") on or about April 21, 2016; and/or 2) on the open market between April 21, 2016 and August 18, 2016 (the "Class Period"), should contact the firm by the October 31, 2016 lead plaintiff motion deadline.

FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against American Renal Associates Holdings, Inc. (ARA) and Lead Plaintiff Deadline: October 31, 2016

2016-10-31 accesswire
NEW YORK, NY / ACCESSWIRE / October 31, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against American Renal Associates Holdings, Inc. ("American Renal Associates" or the "Company") (NYSE: ARA) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased American Renal Associates securities: (1) pursuant and/or traceable to American Renal's Initial Public Offering on or about April 21, 2016 (the "IPO"); and/or (2) from April 21, 2016 through August 18, 2016, inclusive (the "Class Period").

2-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against American Renal Associates Holdings, Inc. and Reminds Investors with Losses to Contact the Firm

2016-10-29 accesswire
IRVINE, CA / ACCESSWIRE / October 29, 2016 / Khang & Khang LLP (the "Firm") announces a class action lawsuit against American Renal Associates Holdings, Inc. ("ARA" or the "Company") (NYSE: ARA). Investors who purchased or otherwise acquired shares 1) pursuant and/or traceable to the Initial Public Offering ("IPO") on or about April 21, 2016; and/or 2) on the open market between April 21, 2016 and August 18, 2016 (the "Class Period"), should contact the Firm by the October 31, 2016 lead plaintiff motion deadline.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in American Renal Associates Holdings, Inc. of Class Action Lawsuit and Upcoming Deadline - ARA

2016-10-29 accesswire
NEW YORK, NY / ACCESSWIRE / October 28, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against American Renal Associates Holdings, Inc. ("American Renal" or the "Company") (NYSE: ARA) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 16-cv-06841, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired American Renal securities: (1) pursuant and/or traceable to American Renal's false and misleading Registration Statement and Prospectus issued in connection with the Company's initial public offering on or about April 21, 2016 (the "IPO" or the "Offering"); and/or (2) on the open market between April 21, 2016 and August 18, 2016, both dates inclusive (the "Class Period").

CUSIP: 029227105